A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies (COVIMAB)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Immunocompromised Patients

Treatments

Other: Data collection

Study type

Observational

Funder types

Other

Identifiers

NCT05439044
APHP220631

Details and patient eligibility

About

Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).

Enrollment

4,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Adult ≥ 18 years old * Patients who received at least one administration of the following therapies: casirivimab-imdevimab, bamlanivimab-etesevimab, tixagevimab-cilgavimab, regdanvimab, sotrovimab or adintrevimab

Exclusion criteria

* Patients opposed to the collection of their personal data

Trial design

4,000 participants in 1 patient group

Patients who have received an anti-SARS-CoV-2 monoclonal antibody
Description:
Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.
Treatment:
Other: Data collection

Trial contacts and locations

1

Loading...

Central trial contact

Marie BENHAMMANI-GODARD; Jeremie Zerbit, PharmD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems